IL81221A0 - Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them - Google Patents

Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them

Info

Publication number
IL81221A0
IL81221A0 IL81221A IL8122187A IL81221A0 IL 81221 A0 IL81221 A0 IL 81221A0 IL 81221 A IL81221 A IL 81221A IL 8122187 A IL8122187 A IL 8122187A IL 81221 A0 IL81221 A0 IL 81221A0
Authority
IL
Israel
Prior art keywords
proteins
husi
inhibitors
biological activity
type
Prior art date
Application number
IL81221A
Other languages
English (en)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of IL81221A0 publication Critical patent/IL81221A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL81221A 1986-01-10 1987-01-09 Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them IL81221A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863600571 DE3600571A1 (de) 1986-01-10 1986-01-10 Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
IL81221A0 true IL81221A0 (en) 1987-08-31

Family

ID=6291649

Family Applications (1)

Application Number Title Priority Date Filing Date
IL81221A IL81221A0 (en) 1986-01-10 1987-01-09 Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them

Country Status (16)

Country Link
US (1) US4845076A (da)
EP (1) EP0232523B1 (da)
JP (2) JP2533869B2 (da)
AT (1) ATE88500T1 (da)
AU (1) AU604003B2 (da)
CA (1) CA1326216C (da)
DE (2) DE3600571A1 (da)
DK (1) DK11187A (da)
ES (1) ES2054612T3 (da)
HU (1) HU204888B (da)
IE (1) IE61526B1 (da)
IL (1) IL81221A0 (da)
LT (1) LTIP1753A (da)
LV (1) LV10490B (da)
PT (1) PT84089B (da)
ZA (1) ZA87141B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
US5851983A (en) * 1987-12-28 1998-12-22 Teijin Limited Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
DE3841873A1 (de) * 1988-12-13 1990-06-21 Gruenenthal Gmbh Neue serinprotease-inhibitor-proteine, diese enthaltende arzneimittel, dna-sequenzen, die fuer diese proteine codieren und verfahren zur herstellung dieser proteine, arzneimittel und dna-sequenzen
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
HUT75660A (en) * 1994-03-23 1997-05-28 Tokyo Tanabe Co Novel remedy for respiratory-tract viral disease
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US6544740B1 (en) * 1999-07-01 2003-04-08 Reprogen, Inc. Treatment of endometriosis with antileukoprotease
EP1400247A1 (en) * 1999-07-01 2004-03-24 Reprogen, Inc. Treatment of endometriosis with antileukoprotease
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
AU2002325108A1 (en) * 2001-08-27 2003-03-10 Les Laboratoires Aeterna Inc. Serine protease inhibitor and processes for the preparation thereof
GB2532488B (en) * 2014-11-21 2019-07-31 Univ Of The Western Cape Use of AMP1 or AMP8 to diagnose HIV infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501291A (ja) * 1984-12-06 1987-05-21 サイナ−ゲン　バイオロジカルズ，インコ−ポレ−テツド 精製セリンプロテアーゼインヒビターおよびこれを含有する医薬組成物
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
DE3587526T3 (de) * 1984-12-06 2002-08-08 Amgen Inc.(N.D.Ges D. Staates Delaware), Thousand Oaks Serinproteaseinhibitoren und isolierungsverfahren dazu.

Also Published As

Publication number Publication date
JPH07300500A (ja) 1995-11-14
EP0232523A2 (de) 1987-08-19
EP0232523B1 (de) 1993-04-21
DK11187A (da) 1987-07-11
CA1326216C (en) 1994-01-18
US4845076A (en) 1989-07-04
ES2054612T3 (es) 1994-08-16
AU604003B2 (en) 1990-12-06
AU6745287A (en) 1987-07-16
HUT43106A (en) 1987-09-28
LTIP1753A (en) 1995-07-25
DE3688324D1 (de) 1993-05-27
LV10490A (lv) 1995-02-20
JPS62259591A (ja) 1987-11-11
ZA87141B (en) 1987-08-26
PT84089A (en) 1987-02-01
HU204888B (en) 1992-02-28
JP2533869B2 (ja) 1996-09-11
DK11187D0 (da) 1987-01-09
EP0232523A3 (en) 1988-12-07
ATE88500T1 (de) 1993-05-15
LV10490B (en) 1995-10-20
PT84089B (pt) 1989-02-28
JP2659525B2 (ja) 1997-09-30
IE61526B1 (en) 1994-11-16
IE870055L (en) 1987-07-10
DE3600571A1 (de) 1987-08-06

Similar Documents

Publication Publication Date Title
AU578050B2 (en) Desulfatohirudins, the preparation thereof and pharmaceutical compositions containing them
AU568067B2 (en) Oligonucleotide therapeutic agent and methods of making same
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
AU3368497A (en) Human dnase i hyperactive variants
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
ZA884216B (en) Proteins with factor viii activity,process for their preparation and pharmaceutical compositions containing them
AU9058091A (en) Preparation of nucleic acid samples
MY102472A (en) Preparation of funtional human urokinase proteins.
EP0151246A3 (en) Polypeptide inhibitor of the activity of alpha-amylase, process for its preparation, its use, and pharmaceutical preparations
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
GR3000944T3 (en) Pharmaceutical composition containing thymus extract fractions
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
AU613583B2 (en) Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
GR3007031T3 (da)
FI896261A7 (fi) Menetelmä proteiinin tai polypeptidin valmistamiseksi, polypeptidiä ko odaava DNA-sekvenssi, DNA-sekvenssin sisältämä mikro-organismi sekä po lypeptidi ja sen käyttö farmaseuttisena valmisteena
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
IE890087L (en) Recombinant human interleukin-1 alpha polypeptides
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
RH Patent void